Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ORGO

3 Penny Stocks to Watch for Big Gains in 2025

The Federal Reserve's recent rate cut indicates a stable yet slowing economy, with inflation sticking around but consumer spending strong. In light of these events, penny stocks, Ribbon Communications (RBBN), Ironwood Pharmaceuticals (IRWD), and Organogenesis Holdings (ORGO), all priced under $5, could make attractive investments. Read on….

StockNews.com

Is Organogenesis a Hidden Gem in the Biotech Sector?

Given Organogenesis’s (ORGO) upbeat first-quarter results and promising development of its ReNu program for knee osteoarthritis, the company seems to be on the brink of significant growth. Let’s delve into its fundamentals to determine whether it's a hidden gem in the biotech sector. Read more to find out….

StockNews.com

3 Biotech Stocks with Potential Gains - Watch or Buy?

The biotech industry’s growth prospects look promising due to advanced technologies like AI, the growing popularity of tailored treatments, a rise in chronic diseases, and higher R&D spending. Let's analyze the investment prospects of biotech stocks Innoviva (INVA), Organogenesis Holdings (ORGO), and Compugen (CGEN). Read more.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Biotech Stock Success: Top 3 Picks for Monthly Gains

Amid the dynamic biotech landscape, the sector is set to witness an upward trajectory fueled by consistent advancements. Therefore, it could be wise to buy fundamentally strong biotech stocks Protalix BioTherapeutics (PLX), Organogenesis Holdings (ORGO), and ANI Pharmaceuticals (ANIP) for monthly gains. Read more.

StockNews.com

4 Biotech Stocks With Massive Buy Potential

The biotech sector is poised for robust long-term growth, driven by significant developments in drug approvals, innovative therapies, and government-backed initiatives. Hence, investors might consider buying fundamentally solid biotech stocks ProQR Therapeutics (PRQR), Foghorn Therapeutics (FHTX), Harmony Biosciences (HRMY), and Organogenesis Holdings (ORGO) with massive buy potential. Keep reading.

StockNews.com

3 Lucrative Biotech Stock Buys for Success

The development of orphan medications, innovative biotech equipment, personalized medicine, and strong government support are all contributing to the biotech industry's upward trajectory. Thus, lucrative biotech stocks Vertex Pharmaceuticals (VRTX), Innoviva (INVA), and Organogenesis Holdings (ORGO) could be ideal additions to your portfolio right now. Read more….

StockNews.com

3 Biotech Stocks to Keep an Eye on in 2024

The biotechnology industry is witnessing remarkable expansion, propelled by notable advances in drug development, an increase in merger and acquisition activities, proliferation of technological innovations, and strong backing from the government. Given this backdrop, quality biotech stocks Acorda Therapeutics (ACOR), Organogenesis Holdings (ORGO), and Equillium (EQ) could be kept an…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Biotech Stock Buys to Supercharge Your Portfolio

The biotechnology industry is flourishing due to the recent breakthroughs in drug development, technological advancements, and strong governmental backing. Given this backdrop, promising biotech stocks Organogenesis Holdings (ORGO), Theratechnologies (THTX), and Vertex Pharmaceuticals (VRTX) could be solid buys to supercharge the portfolios. Read on….

StockNews.com

3 Biotech Stocks Flashing Year-End 'Buy' Signals"

Despite macroeconomic challenges, the biotech industry thrives on innovation, demand, adaptability, and technological advancements, demonstrating resilience and adaptability. So, it could be wise to invest in quality biotech stocks Galapagos (GLPG), Organogenesis (ORGO) and Acorda Therapeutics (ACOR). These stocks are Buy-rated in our proprietary rating system. Read on.

StockNews.com

3 Biotech Stocks Bursting With Investment Potential

The biotech industry is well-positioned for robust growth thanks to the increasing demand for effective treatments for chronic diseases and the need to serve an aging population. To capitalize on the favorable industry trends, investing in quality biotech stocks Organogenesis Holdings (ORGO), Genmab A/S (GMAB), and Incyte (INCY) could be…

StockNews.com

November Buy Alert: 3 Biotech Stocks Making Gains

Given the breakthrough developments and the rising need to treat chronic diseases, the biotech industry is well-positioned to generate returns. This might make buying biotech stocks like Organogenesis Holdings (ORGO), Innoviva (INVA), and Amgen (AMGN) a wise decision this November. Read on….

StockNews.com

Bionano Genomics (BNGO) Challengers: 3 Biotech Innovators to Buy Instead

With the rising aging population and the emergence of new diseases, the biotech industry appears poised for steady growth. Therefore, three quality biotech stocks, Vanda Pharmaceuticals (VNDA), Organogenesis Holdings (ORGO), and Exelixis (EXEL), could be better catches than Bionano Genomics (BNGO). Read on….

StockNews.com

3 Brilliant Biotech Stocks to Buy for Your Portfolio

The biotech industry is flourishing on the backs of positive clinical trials and new developments. Thus, it could be beneficial to add fundamentally robust biotech stocks BioMarin Pharmaceutical (BMRN), Equillium (EQ), and Organogenesis Holdings (ORGO) to your portfolios. Read more….

StockNews.com

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Organogenesis (ORGO) Stock Jumps 5.3%: Will It Continue To Soar?

Organogenesis (ORGO) shares rallied 5.3% in the last trading session to close at $5.19. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 0.4% gain over the past four weeks.

Benzinga

Organogenesis Holdings's Return On Capital Employed Overview

Pulled from Benzinga Pro data, Organogenesis Holdings (NASDAQ:ORGO) posted Q1 earnings of $87.00 thousand, an increase from Q4 of 99.83%. Sales dropped to $98.12 million, a 23.68% decrease between quarters.

Benzinga

Organogenesis Holdings Earnings Perspective: Return On Capital Employed

According to Benzinga Pro, during Q4, Organogenesis Holdings (NASDAQ:ORGO) earned $51.70 million, a 311.03% increase from the preceding quarter. Organogenesis Holdings also posted a total of $128.56 million in sales, a 13.02% increase since Q3.

Benzinga

Organogenesis' Q4 Profit Jumps More than 150% To $54M, Issues Solid FY22 Guidance

Organogenesis Holdings Inc's (NASDAQ: ORGO)

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Recap: Organogenesis Holdings Q4 Earnings

Organogenesis Holdings (NASDAQ:ORGO) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Benzinga

A Preview Of Organogenesis Holdings's Earnings

Organogenesis Holdings (NASDAQ:ORGO) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts estimate that Organogenesis Holdings will report an earnings per share (EPS) of $0.08.

People

Kritika SarmahHer

727 stories

Sristi Suman JayaswalThe

216 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals Incorporated

61 stories

Incyte

58 stories

US Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.